Navigation Links
Egenix Licenses Harvard Anti-Cancer Platform
Date:1/31/2008

MILLBROOK, N.Y., Jan. 31 /PRNewswire/ -- Mr. Donald Fresne, Chairman and CEO of Egenix, Inc., announced today that the company has recently obtained from Harvard University a field-exclusive license under patent rights that cover certain technologies related to cancer therapy and prognostic testing. The licensed technologies, which were developed jointly by scientists in the Laboratory for Translational Research and the Department of Biological Chemistry and Molecular Pharmacology, each of Harvard Medical School, comprise small molecule inhibitors of translation initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anti-cancer therapy with this novel class of anti-cancer drugs. Specifically, the inhibitors of translation initiation licensed by Egenix from Harvard Medical School target the eIF4F and ternary complexes, the two critical regulators of messenger RNA translation into protein.

The company's management believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this cutting-edge platform has the potential to yield significant breakthroughs in the biomedical field for the treatment of cancer.

About Egenix, Inc.

Based in Millbrook, New York, Egenix, Inc. is a privately held biotechnology company responding to the demand for more effective cancer therapies.

Terms and conditions of the license agreement are not disclosed.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
2. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
3. Prometheus Licenses COLAL-PRED(R) From Alizyme
4. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
5. Syngenta Licenses Chromatin Gene Stacking Technology
6. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
7. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
8. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
9. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
10. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2016. The cash dividend of $0.24 ... 2016 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):